Pazopanib: a Novel Multitargeted Tyrosine Kinase Inhibitor

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2007 Feb 10

PMID 17288876

Citations 57

Authors

Guru Sonpavde

Thomas E Hutson

Affiliations

Soon will be listed here.

Abstract

Pazopanib (GW786034) is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. Preclinical evaluation has revealed excellent antiangiogenic and antitumor activity, and synergism was observed in combination with chemotherapeutic drugs. Significant antitumor activity was found in animal models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies.

Citing Articles

IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma.

Deshmukh S, Kelly C, Tinoco G Target Oncol. 2024; 20(1):13-25.

PMID: 39546097 DOI: 10.1007/s11523-024-01115-3.

Perioperative systemic treatments in renal cell carcinoma.

Goswamy R, Kalemoglu E, Master V, Bilen M Front Oncol. 2024; 14:1362172.

PMID: 38841158 PMC: 11151741. DOI: 10.3389/fonc.2024.1362172.

Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth.

Wang K, Liao P, Chang W, Yang C, Su Y, Wu P Front Pharmacol. 2024; 14:1281067.

PMID: 38293667 PMC: 10824963. DOI: 10.3389/fphar.2023.1281067.

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis.

Wang L, Liu W, Broussy S, Han B, Fang H Front Pharmacol. 2024; 14:1307860.

PMID: 38239196 PMC: 10794590. DOI: 10.3389/fphar.2023.1307860.

Aortic dissection induced by vascular endothelial growth factor inhibitors.

Dai S, Zhong Y, Cui H, Zhao J, Li S Front Pharmacol. 2023; 14:1189910.

PMID: 37426822 PMC: 10327890. DOI: 10.3389/fphar.2023.1189910.

References

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

Lindahl P, Johansson B, Leveen P, Betsholtz C . Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 277(5323):242-5. DOI: 10.1126/science.277.5323.242. View

Holmgren L, OReilly M, Folkman J . Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995; 1(2):149-53. DOI: 10.1038/nm0295-149. View

Rini B, Small E . Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2004; 23(5):1028-43. DOI: 10.1200/JCO.2005.01.186. View

Hubbard S, Till J . Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000; 69:373-98. DOI: 10.1146/annurev.biochem.69.1.373. View

Ullrich A, Schlessinger J . Signal transduction by receptors with tyrosine kinase activity. Cell. 1990; 61(2):203-12. DOI: 10.1016/0092-8674(90)90801-k. View

Hartman G, Fraley M, Bilodeau M . Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opin Investig Drugs. 2002; 11(6):737-45. DOI: 10.1517/13543784.11.6.737. View

Renhowe P . Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress. Curr Opin Drug Discov Devel. 2002; 5(2):214-24. View

Arteaga C . Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?. Clin Cancer Res. 2003; 9(4):1231-2. View

10.

Yancopoulos G, Davis S, Gale N, Rudge J, Wiegand S, Holash J . Vascular-specific growth factors and blood vessel formation. Nature. 2000; 407(6801):242-8. DOI: 10.1038/35025215. View

11.

Zetter B . Angiogenesis and tumor metastasis. Annu Rev Med. 1998; 49:407-24. DOI: 10.1146/annurev.med.49.1.407. View

12.

Gschwind A, Fischer O, Ullrich A . The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4(5):361-70. DOI: 10.1038/nrc1360. View

13.

Hutson T, Bukowski R . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2006; 4(4):296-8. DOI: 10.3816/CGC.2006.n.011. View

14.

Adams J, Huang P, Patrick D . A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. Curr Opin Chem Biol. 2002; 6(4):486-92. DOI: 10.1016/s1367-5931(02)00357-5. View

15.

Dancey J, Sausville E . Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003; 2(4):296-313. DOI: 10.1038/nrd1066. View

16.

Mendel D, Laird A, Xin X, Louie S, Christensen J, Li G . In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9(1):327-37. View

17.

Demetri G . Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol. 2001; 28(5 Suppl 17):19-26. View